GE HealthCare Buying Intelerad With Eye on Outpatient Settings

GE HealthCare (Nasdaq: GEHC) has announced plans to acquire imaging company Intelerad for $2.3 billion paid in cash, with the goal of creating a cloud-first  and AI-enabled imaging ecosystem spanning outpatient and ambulatory, teleradiology and hospital settings

Chicago-based GE HealthCare says the acquisition furthers the company’s aim to triple its offerings of cloud-enabled products by 2028.

Intelerad’s cloud-first products are designed for radiology and cardiology and extend across both inpatient and outpatient care settings. Intelerad’s outpatient footprint complements GE HealthCare’s strengths in hospital-based imaging. 

“Intelerad is an outstanding strategic fit and is a pioneer in cloud-based imaging software, with a strong portfolio of world-class solutions across care settings. By combining GE HealthCare’s medical device and AI competence at global scale with Intelerad’s enterprise cloud and imaging expertise, we will be even better positioned to meet the evolving needs of healthcare providers, simplify complex workflows, and drive digital innovation across the industry,” said Roland Rott, President and CEO of Imaging at GE HealthCare, in a statement.

“Joining GE HealthCare marks an exciting new chapter for Intelerad, said Jordan Bazinsky, the CEO of Intelerad, in a statement. “GE HealthCare’s global scale and extensive relationships with key decision makers across hospital systems will fuel the expansion of our connected imaging software offering. Together, we look forward to advancing digital innovation in healthcare and delivering more integrated AI-enabled solutions that empower our customers to tackle their greatest challenges.”

GE foresees financial benefits

GE HealthCare estimates that Intelerad’s revenues in the first full year of ownership will be approximately $270 million, of which approximately 90% is recurring, and Adjusted Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) margin will be in excess of 30%. 

Intelerad revenue is growing in the low-double-digit range annually and GE  expects it to accelerate in the combined entity. Upon close, GE HealthCare expects this transaction to be immediately accretive to top line growth and Adjusted Earnings Before Interest and Taxes (EBIT) margin.

Inclusive of the impact of financing costs, GE HealthCare expects the transaction to be slightly dilutive to Adjusted Earnings Per Share (EPS)  in the short term, and the company plans to offset this with cost efficiencies. GE HealthCare expects a high-single-digit return on invested capital by year five.

The transaction is expected to be completed in the first half of 2026, subject to customary closing conditions and regulatory approvals.